Does the initial selection of drug classes approved for monotherapy of early-stage PD (levodopa, dopamine agonists, MAO-B-inhibitors, amantadine, anticholinergics) influence the long-term course of the disease (e.g., development of fluctuations or dyskinesias)? This evidence concerns the gene MAOB and Dyskinesia.